WCN25-4621 Cilnidipine – a Novel CCB reduces blood pressure, heart rate and proteinuria in Indian Hypertensive Patients
About 36% of the Indian population suffers from hypertension, with many patients having uncontrolled blood pressure [BP] despite treatment. Calcium Channel Blockers [CCB] are widely prescribed in India and Southeast Asia, either as monotherapy or in combination with other AHDs, and have proven efficacy and safety. Cilnidipine, a novel CCB, has shown promising results in controlled trials in Southeast Asia, but there is no real-world Indian data available.
Authors
- Deepak Dewan
- Aafreen Naik
- Kapil Dev Metha
Institutions
- Tata Chemicals (India) (IN)
- Serdia Pharmaceuticals (India) (IN)
- BLK Super Speciality Hospital (IN)
Publication Details
- Journal
- Kidney International Reports
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1016/j.ekir.2024.11.644
- Primary Topic
- Heart Rate Variability and Autonomic Control
- Type
- article
- Field-Weighted Citation Impact
- 0.00